Published in PLoS One on November 29, 2010
Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol (2012) 3.10
A central role for RAF→MEK→ERK signaling in the genesis of pancreatic ductal adenocarcinoma. Cancer Discov (2012) 1.87
Potential pitfalls of crossover and thoughts on iniparib in triple-negative breast cancer. J Natl Cancer Inst (2011) 1.50
Genomic complexity and AKT dependence in serous ovarian cancer. Cancer Discov (2012) 1.50
Biomarkers of response to Akt inhibitor MK-2206 in breast cancer. Clin Cancer Res (2012) 1.44
Sensitization of cancer cells through reduction of total Akt and downregulation of salinomycin-induced pAkt, pGSk3β, pTSC2, and p4EBP1 by cotreatment with MK-2206. Biomed Res Int (2014) 1.41
MK-2206, a novel allosteric inhibitor of Akt, synergizes with gefitinib against malignant glioma via modulating both autophagy and apoptosis. Mol Cancer Ther (2011) 1.33
Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl Lung Cancer Res (2015) 1.29
STAT3 mediates resistance to MEK inhibitor through microRNA miR-17. Cancer Res (2011) 1.24
PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes. Acta Pharmacol Sin (2012) 1.15
Testing of the Akt/PKB inhibitor MK-2206 by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer (2011) 1.13
Activation of AKT by hypoxia: a potential target for hypoxic tumors of the head and neck. BMC Cancer (2012) 1.11
Antitumor activity in RAS-driven tumors by blocking AKT and MEK. Clin Cancer Res (2014) 1.05
The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells. J Clin Endocrinol Metab (2011) 1.04
Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response. J Clin Invest (2012) 1.04
Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype. PLoS One (2012) 1.03
Inhibition of AKT with the orally active allosteric AKT inhibitor, MK-2206, sensitizes endometrial cancer cells to progestin. PLoS One (2012) 1.03
AKT is a therapeutic target in myeloproliferative neoplasms. Leukemia (2013) 1.01
Activation of MDL-1 (CLEC5A) on immature myeloid cells triggers lethal shock in mice. J Clin Invest (2011) 1.01
Phosphatidylinositol 3-kinase/Akt signaling pathway activates the WNK-OSR1/SPAK-NCC phosphorylation cascade in hyperinsulinemic db/db mice. Hypertension (2012) 0.99
Blocks to thyroid cancer cell apoptosis can be overcome by inhibition of the MAPK and PI3K/AKT pathways. Cell Death Dis (2014) 0.96
Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia. Clin Cancer Res (2014) 0.94
KEAP1-dependent synthetic lethality induced by AKT and TXNRD1 inhibitors in lung cancer. Cancer Res (2013) 0.93
Synergistic and antagonistic drug combinations depend on network topology. PLoS One (2014) 0.92
Targeting non-small cell lung cancer cells by dual inhibition of the insulin receptor and the insulin-like growth factor-1 receptor. PLoS One (2013) 0.89
IGFBP2/FAK pathway is causally associated with dasatinib resistance in non-small cell lung cancer cells. Mol Cancer Ther (2013) 0.89
Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells. Br J Cancer (2012) 0.88
Discovery of Drug Synergies in Gastric Cancer Cells Predicted by Logical Modeling. PLoS Comput Biol (2015) 0.84
KRAS mutant NSCLC, a new opportunity for the synthetic lethality therapeutic approach. Transl Lung Cancer Res (2013) 0.84
Titration of signalling output: insights into clinical combinations of MEK and AKT inhibitors. Ann Oncol (2015) 0.83
Inactivation of AKT induces cellular senescence in uterine leiomyoma. Endocrinology (2014) 0.82
Targeting MEK for the treatment of non-small-cell lung cancer. J Thorac Oncol (2012) 0.82
Effects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung cancer cell lines. J Cancer Res Clin Oncol (2014) 0.82
Targeting mTOR signaling pathways and related negative feedback loops for the treatment of acute myeloid leukemia. Cancer Biol Ther (2015) 0.80
MK-2206, an AKT inhibitor, promotes caspase-independent cell death and inhibits leiomyoma growth. Endocrinology (2013) 0.80
Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors. Invest New Drugs (2014) 0.80
SAHA and S116836, a novel tyrosine kinase inhibitor, synergistically induce apoptosis in imatinib-resistant chronic myelogenous leukemia cells. Cancer Biol Ther (2014) 0.79
BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer. Invest New Drugs (2014) 0.78
Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer. Sci Rep (2015) 0.78
Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors. Oncotarget (2015) 0.78
Mutant PIK3CA controls DUSP1-dependent ERK 1/2 activity to confer response to AKT target therapy. Br J Cancer (2014) 0.78
Dual Inhibition of PI3K/AKT and MEK/ERK Pathways Induces Synergistic Antitumor Effects in Diffuse Intrinsic Pontine Glioma Cells. Transl Oncol (2017) 0.77
Evaluation of efficacy of a new MEK inhibitor, RO4987655, in human tumor xenografts by [(18)F] FDG-PET imaging combined with proteomic approaches. EJNMMI Res (2014) 0.77
Vertical Targeting of AKT and mTOR as Well as Dual Targeting of AKT and MEK Signaling Is Synergistic in Hepatocellular Carcinoma. J Cancer (2015) 0.76
Trends in Personalized Therapies in Oncology: The (Venture) Capitalist's Perspective. J Pers Med (2012) 0.76
AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin. PLoS One (2013) 0.76
Animal models in carotenoids research and lung cancer prevention. Transl Oncol (2011) 0.76
In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor. Anticancer Drugs (2017) 0.75
Biocompatible astaxanthin as a novel marine-oriented agent for dual chemo-photothermal therapy. PLoS One (2017) 0.75
Combined Targeting of mTOR and Akt Using Rapamycin and MK-2206 in The Treatment of Tuberous Sclerosis Complex. J Cancer (2017) 0.75
MEK inhibitors block growth of lung tumours with mutations in ataxia-telangiectasia mutated. Nat Commun (2016) 0.75
Microscale Symmetrical Electroporator Array as a Versatile Molecular Delivery System. Sci Rep (2017) 0.75
A novel PI3K inhibitor iMDK suppresses non-small cell lung Cancer cooperatively with A MEK inhibitor. Exp Cell Res (2015) 0.75
Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth. J Clin Invest (2017) 0.75
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med (2008) 14.47
Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res (2010) 12.96
Regulation of cell death protease caspase-9 by phosphorylation. Science (1998) 11.26
Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature (2001) 10.56
Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res (2007) 5.59
ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. Nat Cell Biol (2008) 5.19
The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell (2005) 4.48
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci U S A (2009) 4.02
KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer. Mol Cancer Ther (2009) 2.22
Dissociation of cytokine-induced phosphorylation of Bad and activation of PKB/akt: involvement of MEK upstream of Bad phosphorylation. Proc Natl Acad Sci U S A (1998) 2.06
BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins. Cancer Res (2008) 2.03
BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines. J Clin Endocrinol Metab (2008) 1.95
High level of AKT activity is associated with resistance to MEK inhibitor AZD6244 (ARRY-142886). Cancer Biol Ther (2009) 1.86
Targeting protein translation in human non small cell lung cancer via combined MEK and mammalian target of rapamycin suppression. Cancer Res (2007) 1.55
Optimizing combination chemotherapy by controlling drug ratios. Mol Interv (2007) 1.55
Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines. Int J Cancer (2009) 1.44
KRAS mutations predict response to EGFR inhibitors. Curr Opin Pharmacol (2008) 1.41
LKB1/KRAS mutant lung cancers constitute a genetic subset of NSCLC with increased sensitivity to MAPK and mTOR signalling inhibition. Br J Cancer (2009) 1.33
Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines. Mol Cancer Ther (2010) 1.30
KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer. Br J Cancer (2008) 1.24
Drug ratio-dependent antitumor activity of irinotecan and cisplatin combinations in vitro and in vivo. Mol Cancer Ther (2009) 1.07
Apoptosis induction by MEK inhibition in human lung cancer cells is mediated by Bim. PLoS One (2010) 1.05
Dependence on phosphoinositide 3-kinase and RAS-RAF pathways drive the activity of RAF265, a novel RAF/VEGFR2 inhibitor, and RAD001 (Everolimus) in combination. Mol Cancer Ther (2010) 0.98
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature (2009) 18.39
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst (2005) 13.00
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol (2005) 9.95
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. J Clin Oncol (2004) 8.83
BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res (2002) 8.55
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol (2004) 7.87
The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov (2011) 7.57
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 7.48
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med (2013) 6.70
Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med (2015) 6.28
Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol (2008) 5.98
Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res (2004) 5.57
Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell (2007) 5.09
Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest (2009) 5.07
Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature (2007) 4.70
Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet (2012) 4.70
Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One (2009) 4.62
KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res (2007) 4.45
Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res (2005) 4.25
Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res (2002) 4.19
Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. J Clin Oncol (2003) 4.07
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol (2005) 4.04
Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res (2005) 3.98
Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer (2004) 3.83
Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays. Clin Cancer Res (2005) 3.79
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res (2012) 3.48
Involvement of AGO1 and AGO2 in mammalian transcriptional silencing. Nat Struct Mol Biol (2006) 3.46
Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. Cancer Res (2006) 3.45
Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers? Trends Mol Med (2004) 3.44
PIK3CA mutations and copy number gains in human lung cancers. Cancer Res (2008) 3.42
Focus on lung cancer. Cancer Cell (2002) 3.41
Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin Cancer Res (2006) 3.40
FoxM1B is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells. Cancer Res (2006) 3.28
Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther (2005) 3.27
Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines. Cancer Res (2006) 3.21
Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer. Cancer Cell (2006) 3.20
Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res (2004) 3.20
American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol (2014) 3.20
Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol (2007) 3.19
PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res (2009) 3.13
Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol (2005) 3.12
To kill a tumor cell: the potential of proapoptotic receptor agonists. J Clin Invest (2008) 3.05
Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers. Oncogene (2002) 2.92
Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol (2008) 2.85
Expression of nicotinic acetylcholine receptor subunit genes in non-small-cell lung cancer reveals differences between smokers and nonsmokers. Cancer Res (2007) 2.81
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst (2012) 2.79
Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. PLoS One (2009) 2.79
Mechanism of activation and inhibition of the HER4/ErbB4 kinase. Structure (2008) 2.79
Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J Clin Oncol (2007) 2.77
Bayesian adaptive design for targeted therapy development in lung cancer--a step toward personalized medicine. Clin Trials (2008) 2.71
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov (2012) 2.68
Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol (2008) 2.68
EGFR-mediated Beclin 1 phosphorylation in autophagy suppression, tumor progression, and tumor chemoresistance. Cell (2013) 2.63
Risk factors associated with atrial fibrillation after noncardiac thoracic surgery: analysis of 2588 patients. J Thorac Cardiovasc Surg (2004) 2.62
Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. J Clin Oncol (2010) 2.58
Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. Cancer Res (2010) 2.54
EGF-induced ERK activation promotes CK2-mediated disassociation of alpha-Catenin from beta-Catenin and transactivation of beta-Catenin. Mol Cell (2009) 2.50
ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time. Cancer Cell (2010) 2.50
Posttherapy pathologic stage predicts survival in patients with esophageal carcinoma receiving preoperative chemoradiation. Cancer (2005) 2.49
Amplification of chromosomal segment 4q12 in non-small cell lung cancer. Cancer Biol Ther (2009) 2.47
Gleevec inhibits beta-amyloid production but not Notch cleavage. Proc Natl Acad Sci U S A (2003) 2.44
A translational view of the molecular pathogenesis of lung cancer. J Thorac Oncol (2007) 2.43
Inhibiting gene expression at transcription start sites in chromosomal DNA with antigene RNAs. Nat Chem Biol (2005) 2.34
Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J Clin Oncol (2006) 2.32
[18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol (2005) 2.30
Generalizability of cancer clinical trial results: prognostic differences between participants and nonparticipants. Cancer (2006) 2.30
Molecular genetics of lung cancer. Annu Rev Med (2001) 2.25
Methodological and practical challenges for personalized cancer therapies. Nat Rev Clin Oncol (2011) 2.25
Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death. J Natl Cancer Inst (2007) 2.23
Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2008) 2.22
Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324. J Clin Oncol (2011) 2.21
Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase. J Natl Cancer Inst (2008) 2.21
Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys (2011) 2.18
Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg (2004) 2.18
EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. Cancer Res (2005) 2.17